Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Langford

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
BMJ (Clinical Research Ed.)|July 15, 2021
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analysesTing Cai, Lucy Abel, Oliver Langford, et al.
JAMA Neurology|August 25, 2025
Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer DiseasePhilip S Insel, Niklas Mattsson-Carlgren, Oliver Langford, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 27, 2025
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemabDoris P Molina-Henry, Rema Raman, Andy Liu, et al.
Journal of Alzheimer'S Disease : JAD|January 30, 2023
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's DiseaseCharisse N Winston, Oliver Langford, Natalie Levin, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2020
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 StudyGad A Marshall, Sietske A M Sikkes, Rebecca E Amariglio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumColin Birkenbihl, Hannah M Klinger, Michael J Properzi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsColin Birkenbihl, Hannah M Klinger, Michael J Properzi, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
BMJ (Clinical Research Ed.)|July 15, 2021
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analysesTing Cai, Lucy Abel, Oliver Langford, et al.
JAMA Neurology|August 25, 2025
Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer DiseasePhilip S Insel, Niklas Mattsson-Carlgren, Oliver Langford, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 29, 2021
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort studyKenichiro Sato, Ryoko Ihara, Kazushi Suzuki, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 27, 2025
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemabDoris P Molina-Henry, Rema Raman, Andy Liu, et al.
Journal of Alzheimer'S Disease : JAD|January 30, 2023
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's DiseaseCharisse N Winston, Oliver Langford, Natalie Levin, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2020
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 StudyGad A Marshall, Sietske A M Sikkes, Rebecca E Amariglio, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 17, 2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trialDoris Patricia Molina-Henry, Rema Raman, Andy Liu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumColin Birkenbihl, Hannah M Klinger, Michael J Properzi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Clinical ManifestationsColin Birkenbihl, Hannah M Klinger, Michael J Properzi, et al.
Pageof 3